Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 345-352

  Karanikas, Vaios ^a,b   Tsochas, Stefanos ^a   Boukas, Konstantinos ^a   Kerenidi, Theodora ^a   Nakou, Marianna ^a   Dahabreh, Jubrail ^b   Poularakis, Theodoros ^a   Gourgoulianis, Konstantinos I ^a   Germenis, Anastasios E ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

Author keywords

Human telomerase reverse transcriptase; Immunotherapy; Lung adenocarcinoma; Melanoma associated antigen; p53; Quantitative real time PCR; Squamous cell carcinoma; Survivin

Indexed keywords

BETA ACTIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; PROTEIN P53; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

EID: 45349108941     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5424     Document Type: Article

References (54)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science 2004; 305:200-5
2. Van den Eynde, BJ., and van der Bruggen, P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9:684-93.
3. Davis ID, Jefford M, Parente P, Cebon, J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73:3-29.
4. Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol 2006; 1:93-104.
5. Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. Lung Cancer 2003; 41:5103-13.
6. Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother 2003; 26:357-66.
7. Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Lienard D, Lejeune F, Cerottini JC, Romero P, Speiser DE. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003; 3:15.
8. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitie MA, Lienard D, Dreno B, Velu T, Boon T, Coulie PG. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171:4898-904.
9. Krug LM. Vaccine therapy for small cell lung cancer. Semin Oncol 2004; 31:112-6.
10. Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?" Cancer Immunol Immunother 2007; 56:1921-30.
11. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003; 9:5559-65.
12. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol 2005; 17:320-5.
13. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11:8055-62.
14. Schultz IJ, Witjes JA, Swinkels DW, de Kok JB. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on surviving. Clin Chim Acta 2006; 368:20-32.
15. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Takahashi T, Mitsudomi T. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003; 42:23-33.
16. Tsai JR, Chong IW, Chen YH, Yang MJ, Sheu CC, Chang HC, Hwang JJ, Hung JY, Lin SR. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 2007; 56:185-92.
17. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, Santambrogio L, Coggi G, Bosari S. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003; 200:620-6.
18. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005; 49:353-61.
19. Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C, Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004; 90:1222-9.
20. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K. Expression of the p53 family in lung cancer. Anticancer Res 2006; 26:1785-90.
21. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007; 120:337-43.
22. Stark AM, Hugo HH, Tscheslog H, Mehdorn HM. p53, BCL-2 and BAX in non-small cell lung cancer brain metastases: a comparison of real-time RT-PCR, ELISA and immunohistochemical techniques. Neurol Res 2007; 29:435-40.
23. Ichiki Y, Takenoyama M, Mizukami M, So T, Sugaya M, Yasuda M, So T, Hanagiri T, Sugio K, Yasumoto K. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004; 172:4844-50.
24. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-9.
25. Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 2005; 48:281-9.
26. Bachinsky MM, Guillen DE, Patel SR, Singleton J, Chen C, Soltis DA, Tussey LG. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun 2005; 5:6.
27. Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998; 28:305-16.
28. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 2002; 62:2600-5.
29. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004; 172:3289-96.
30. Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trumper L, Schroers R. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum Immunol 2007; 68:572-6.
31. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4:317-27.
32. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60:4855-63.
33. Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, Brittner B, Ludwig B, Schilling M. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes 2005; 19:101-9.
34. Blanquicett C, Johnson MR, Heslin M, Diasio RB. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: Applications in pharmacogenomic gene expression studies. Analytical Biochemistry 2002; 303:209-14.
35. Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2005; 342:69-77.
36. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 2006; 290:1067-74.
37. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005; 305:300-11.
38. Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004; 23:8146-53.
39. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17:2100-4.
40. Hara H, Yamashita K, Shinada J, Yoshimura H, Kameya T. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 2001; 34:219-26.
41. Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 2006; 94:1452-9.
42. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, Gaudernack G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553-64.
43. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007; 25:2727-34.
44. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273:11177-82.
45. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007; 249:49-60.
46. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7:602-8.
47. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8:1731-9.
48. Blackburn EH. Structure and function of telomeres. Nature 1991; 350:569-73.
49. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21:674-9.
50. Meeker AK, De Marzo AM. Recent advances in telomere biology: implications for human cancer. Curr Opin Oncol 2004; 16:32-8.
51. Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188:33-42.
52. Boon T, Coulie PG, van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208.
53. Vansteenkiste J, Zielinski M, Dahabre J, Linder A, Malinowski W, Jassem J, Lopez-Brea M, Passlick B, Lehmann F, Brichard V. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). J Clin Oncol 2006; ASCO Annual Meeting Proceedings I (24):18S, 7019.
54. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard VG. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; ASCO Annual Meeting Proceedings I (25):18S, 7554.